- Home
- SRV vs SWKH Comparison
SRV vs SWKH Comparison
Compare SRV & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRV
- SWKH
- Stock Information
- Founded
- SRV 2007
- SWKH 1996
- Country
- SRV United States
- SWKH United States
- Employees
- SRV N/A
- SWKH N/A
- Industry
- SRV Finance Companies
- SWKH Diversified Financial Services
- Sector
- SRV Finance
- SWKH Finance
- Exchange
- SRV Nasdaq
- SWKH Nasdaq
- Market Cap
- SRV 183.6M
- SWKH 179.1M
- IPO Year
- SRV N/A
- SWKH 1999
- Fundamental
- Price
- SRV $41.65
- SWKH $15.28
- Analyst Decision
- SRV
- SWKH Strong Buy
- Analyst Count
- SRV 0
- SWKH 1
- Target Price
- SRV N/A
- SWKH $18.00
- AVG Volume (30 Days)
- SRV 33.9K
- SWKH 15.0K
- Earning Date
- SRV 01-01-0001
- SWKH 08-14-2025
- Dividend Yield
- SRV 13.38%
- SWKH N/A
- EPS Growth
- SRV N/A
- SWKH 51.50
- EPS
- SRV N/A
- SWKH 1.41
- Revenue
- SRV N/A
- SWKH $34,906,000.00
- Revenue This Year
- SRV N/A
- SWKH $52.93
- Revenue Next Year
- SRV N/A
- SWKH N/A
- P/E Ratio
- SRV N/A
- SWKH $10.83
- Revenue Growth
- SRV N/A
- SWKH 18.02
- 52 Week Low
- SRV $30.73
- SWKH $12.00
- 52 Week High
- SRV $44.30
- SWKH $16.24
- Technical
- Relative Strength Index (RSI)
- SRV 49.00
- SWKH 60.17
- Support Level
- SRV $41.35
- SWKH $15.07
- Resistance Level
- SRV $42.19
- SWKH $15.28
- Average True Range (ATR)
- SRV 0.48
- SWKH 0.17
- MACD
- SRV -0.10
- SWKH -0.02
- Stochastic Oscillator
- SRV 26.69
- SWKH 88.37
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.